Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 83, Issue 1, Pages 112-122Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2011.08.008
Keywords
Kidney; Cancer; Progression; Target; Therapy
Categories
Ask authors/readers for more resources
In the last 5 years inhibitors of the VEGFNEGFR and mTOR pathways have dramatically changed the therapeutic approach to metastatic renal cancer. Randomized controlled trials have shown that six targeted agents - sorafenib, sunitinib, temsirolimus, bevacizumab, everolimus and pazopanib are able to improve patient outcome. Even if the choice of drug for first-line therapy is quite well defined, to date it is not easy to characterize and evaluate the efficacy of new therapies in second-line treatment. It is not clear whether, after first-line therapy with a VEGF/VEGFR inhibitor, use of mTOR or a second TKI inhibitor should be recommended. In this review we report on current evidence supporting the use of targeted agents in second-line therapy. Therefore we try to combine current clinical results with a practical clinical approach, with the goal of evaluating the best clinical decision for different clinical situations. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available